Introduction
============

Tardive dystonia and dyskinesia are potentially irreversible neurological syndromes. They are characterized by choreiform and athetoid movements that primarily affect the buccal, facial, and lingual muscles, but may also affect the extremities and trunk. In neuroleptic-treated patients, the estimated prevalence of tardive dyskinesia is 15%--20%,[@b1-ndt-10-1209] with a range of 0.5%--56%.[@b2-ndt-10-1209],[@b3-ndt-10-1209] In one study, the cumulative rates of tardive dyskinesia after 1, 2, and 3 years of antipsychotic treatment were 25%, 34%, and 53%, respectively.[@b4-ndt-10-1209] A greater risk of tardive dyskinesia has been associated with; a history of electroconvulsive treatment (ECT), higher mean daily and cumulative antipsychotic doses, and the presence of extrapyramidal signs early in treatment.[@b4-ndt-10-1209],[@b5-ndt-10-1209]

Several case reports have described the successful application of ECT to treat tardive dystonia[@b6-ndt-10-1209]--[@b9-ndt-10-1209] and dyskinesia.[@b2-ndt-10-1209],[@b10-ndt-10-1209]--[@b13-ndt-10-1209] These case reports suggest that a publication bias may be overemphasizing the positive results. While a retrospective review or an open prospective trial should provide a clearer picture of the response rates by including the nonresponders, there has been little information on the response rates for ECT. Therefore, we examined the effects of ECT on tardive dystonia and dyskinesia.

Methods
=======

This study was approved by the local ethics committee of Hirosaki University Hospital and was carried out in accordance with the latest version of the Declaration of Helsinki. All participants provided written informed consent prior to participation in the study.

ECTs were performed in approximately 15 patients per year in our university hospital between 2005 and 2010. The aim of ECT is to treat depression, Schizophrenia symptoms, and movement disorders. Seventy-four patients were treated with ECT, including 39 patients with depression affective disorders, 15 patients with Schizophrenia, two patients with neurosis, and 18 patients with tardive involuntary movement disorders. The subjects included in this study consisted of 18 consecutive patients with tardive involuntary movement disorders who underwent ECT. [Table 1](#t1-ndt-10-1209){ref-type="table"} provides descriptive data on the demographic and clinical characteristics of the 18 subjects. The pharmacological histories of the subjects were unknown. No psychopathological evaluations other than establishing abnormal involuntary movements were conducted because the mental conditions of all subjects were stable.

Tardive dystonia and dyskinesia were assessed using the Abnormal Involuntary Movements Scale (AIMS),[@b14-ndt-10-1209] with repeated administrations throughout the course of ECT. A response was defined as a 50% improvement relative to the baseline, and a partial response was defined as a 25% improvement relative to the baseline. The subjects included ten women and eight men between the ages of 19 and 65 years (mean ± standard deviation =42±14); 13 patients had been diagnosed with Schizophrenia, and the remaining five patients had been diagnosed with unipolar depression. The patients were prescribed one or two antidepressants or antipsychotic medications during ECT. The medications were maintained at a constant rate during the course of ECT, with only minor dosage adjustments and no absolute changes to the antidepressant or antipsychotic agents.

All patients received bilateral ECT, which was performed three times per week, using a Thymatron^®^ machine (Nihon Koden Medical, Tokyo, Japan). Each ECT procedure was conducted between 8.30 am and 10 am at Hirosaki University Hospital. Patients fasted for at least 12 hours before the ECT procedure. During each ECT procedure, 0.5--1 mg/kg propofol was administered intravenously to each patient, and succinylcholine (0.5 mg/kg) was administered as a muscle relaxant after the induction of anesthesia. The stimulus intensity was determined with a dose titration procedure (starting at 25.2 millicoulomb), and the seizure threshold was identified in the first session. The electrical dose was then determined by multiplying the seizure threshold dose by 2.5 in the following sessions. The seizure duration (tonic and clonic) was recorded by the isolation of one leg by inflation of a cuff to over 200 mmHg to assess the quality of the seizure. If the duration of the seizure was less than 20 seconds, then the electrical dose was increased by 50%. The patients' ventilation was supported using 100% oxygen through a bag and mask until the resumption of respiration. We continuously monitored the electrocardiogram, arterial oxygen saturation (pulse oximetry), noninvasive blood pressure, and heart rate of the patients during the procedure. The length of the ECT course ranged from six to 15 treatments administered twice per week. The average overall course length was 10.5±2.4 treatments. If the patients had no response to ECT, they declined ECT after the sixth session.

Several factors, including the AIMS and Global Assessment of Functioning scores, were compared using paired *t*-tests. Multiple regression analyses were used to detect the correlations between the degree of improvement in the AIMS score and several factors, including; age, sex, the type of movement disorder, the diagnosis, and the baseline AIMS score. Sex, the type of movement disorder, and the diagnosis were analyzed using dummy variables (male =0, female =1, tardive dyskinesia =0, tardive dystonia =1, depression =0, schizophrenia =1). A *P*-value of less than 0.05 was regarded as statistically significant. All analyses were performed using PASW Statistics PC software for Windows, Version 21.0.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

[Figure 1](#f1-ndt-10-1209){ref-type="fig"} shows the changes in the AIMS scores throughout the course of the ECT for each subject. The mean AIMS score decreased from 19.1±4.7 to 9.6±4.2. Out of 18 patients, seven patients were responders, and eleven patients were partial responders following the ECT. There were no nonresponders. Out of the seven responders, four patients responded within two sessions. A total of 39% of the patients were responders and showed a greater than 50% improvement in their AIMS scores. The mean AIMS score significantly decreased and showed a 40% improvement. All patients tolerated the ECT well and did not present any serious adverse effects. Four patients reported a mild headache and scalp discomfort during the first several treatments, but these side effects subsided quickly. The Global Assessment of Functioning score significantly increased from 30.6±5.2 to 50.0±6.7 (*P*\<0.001).

Multiple regression analyses, including; sex, age, the type of movement disorder, the diagnosis, and the baseline AIMS score, revealed no correlations with the degree of improvement in the AIMS score.

There were no differences in the parameters of ECT delivery or the clinical information between the responders and the nonresponders.

Discussion
==========

The results of our study indicate the effectiveness of ECT as a treatment for tardive dystonia and tardive dyskinesia. However, the efficacy of ECT for tardive dystonia and tardive dyskinesia was mild to moderate. This report is the first to provide the ECT response rate (39%) for tardive dystonia and tardive dyskinesia. In some patients, ECT was effective within two sessions. While the response rate is not high and predicting symptom improvement is difficult, clinicians should consider ECT for patients with tardive dystonia and tardive dyskinesia. Because medication remained constant throughout the course of ECT in this study, the 39% response rate is likely accurate.

While the successful treatment of tardive dystonia and dyskinesia using ECT has been suggested in previous case reports, the single prospective study[@b7-ndt-10-1209] observed an improvement in only one patient, while eight patients remained unchanged. Many patients have undergone changes in their medication regimen. These changes may cause a withdrawal dyskinesia that spontaneously remits over time.[@b15-ndt-10-1209]

ECT is thought to prevent the supersensitization of the postsynaptic dopamine receptors that contribute to the development of tardive states.[@b16-ndt-10-1209],[@b17-ndt-10-1209] These effects only occurred with concurrent neuroleptic administration, which may account for the efficacy of ECT in both hypo and hyperdopaminergic states.[@b16-ndt-10-1209] Several mechanisms of action have been proposed for ECT in tardive dyskinesia and tardive dystonia. The most commonly accepted explanation is that ECT enhances dopaminergic transmission. This enhancement may occur at the receptor or postreceptor level.[@b17-ndt-10-1209] Animal studies have demonstrated an upregulation of the GABAergic system. A change in the GABAergic system may influence abnormal movement disorders, but the evidence remains controversial. Another explanation may involve the disruption of the blood--brain barrier, which is known to occur after ECT.[@b18-ndt-10-1209] This disruption may allow increased levels of antipsychotics and antidepressants to enter the brain, potentially alleviating the motor symptoms even while the oral dose of the drug remains constant.[@b19-ndt-10-1209]

There are several limitations to this case series. First, longitudinal changes in cognitive function were not evaluated after the course of ECT. ECT has been frequently discontinued because of the adverse cognitive effects; thus, the assessment of cognitive function and recovery during the course of ECT would be an important measure to include in a prospective study. Second, while the type and dose of medications were held constant in all patients, we were unable to control for the confounding effects of medication. Finally, this case series is limited by the retrospective design and the lack of a control group. Despite these limitations, this case series suggests that ECT may offer another potential treatment for tardive dystonia and tardive dyskinesia. Controlled studies comparing ECT to current evidenced-based strategies such as vitamin E are warranted.[@b20-ndt-10-1209] Future studies should also include comprehensive measures of cognition.

The authors would like to thank all of their coworkers on this study for their skillful contributions to collecting and managing the data.

This study was funded by a Grant-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Research (JSPS, \# 22591271), Mitsubishi Pharma Research Foundation. Asteras Schizophrenia Research Foundation and a grant from the Hirosaki Research Institute for Neurosciences.

**Disclosure**

Norio Yasui-Furukori has received grant/research support or honoraria from, and been on the speakers of Astra, Dainippon, Eli Lilly, GSK, Janssen-Pharma, Meiji. Mochida, MSD, Otsuka, Pfizer, Takada and Yoshitomi. The remaining authors declare that they have no competing interests. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

![Individual AIMS score over ECT course.\
**Note:** Significant decrease in AIMS score over number of ECT was found (*P*\<0.001).\
**Abbreviations:** AIMS, Abnormal Involuntary Movement Scale; ECT, electroconvulsive treatment.](ndt-10-1209Fig1){#f1-ndt-10-1209}

###### 

Characteristics of the 18 subjects

  Patient number   Age (years)   Sex   Type of tardive disorder   Diagnosis       Potential causal medication and their daily doses   Current medications and their daily doses   Number of sessions   AIMS scores   Outcome   
  ---------------- ------------- ----- -------------------------- --------------- --------------------------------------------------- ------------------------------------------- -------------------- ------------- --------- ----
  1                65            F     Dyskinesia                 Depression      Milnacipran 60 mg/day                               No medication                               6                    14            2         R
  2                62            F     Dyskinesia                 Depression      Haloperidol 6 mg/day                                Risperidone 2 mg/day                        12                   22            10        R
  3                63            F     Dyskinesia                 Depression      Haloperidol 12 mg/day                               Olanzapine 5 mg/day                         10                   18            10        PR
  4                33            M     Dyskinesia                 Schizophrenia   Risperidone 6 mg/day                                Olanzapine 2.5 mg/day                       10                   23            2         R
  5                30            M     Dyskinesia                 Schizophrenia   Olanzapine 20 mg/day                                Aripiprazole 3 mg/day                       10                   20            12        PR
  6                62            F     Dystonia                   Depression      Milnacipran 100 mg/day                              No medication                               10                   24            13        PR
  7                54            M     Dystonia                   Schizophrenia   Chlorpromazine 600 mg/day                           Olanzapine 10 mg/day                        10                   11            3         R
  8                28            M     Dystonia                   Schizophrenia   Risperidone 6 mg/day                                Risperidone 2 mg/day                        9                    21            6         R
  9                30            M     Dystonia                   Schizophrenia   Risperidone 4 mg/day                                Risperidone 1 mg/day                        10                   22            13        PR
  10               32            M     Dystonia                   Schizophrenia   Risperidone 8 mg/day                                Risperidone 2 mg/day                        12                   25            14        PR
  11               37            M     Dystonia                   Schizophrenia   Perospirone 24 mg/day                               Risperidone 3 mg/day                        15                   26            17        PR
  12               59            F     Dyskinesia                 Schizophrenia   Perospirone 48 mg/day                               Aripiprazole 12 mg/day                      8                    16            7         R
  13               55            F     Dyskinesia                 Depression      Sulpiride 150 mg/day                                No medication                               15                   21            12        PR
  14               39            F     Dystonia                   Schizophrenia   Mosapramine 150 mg/day                              No medication                               10                   13            10        PR
  15               33            F     Dystonia                   Schizophrenia   Perospirone 12 mg/day                               Aripiprazole 3 mg/day                       15                   21            10        R
  16               19            F     Dystonia                   Schizophrenia   Risperidone 4 mg/day                                Aripiprazole 3 mg/day                       10                   12            7         PR
  17               28            M     Dyskinesia                 Schizophrenia   Perospirone 12 mg/day                               Aripiprazole 1.5 mg/day                     8                    12            9         PR
  18               32            F     Dystonia                   Schizophrenia   Aripiprazole 24 mg/day                              Aripiprazole 3 mg/day                       8                    23            15        PR

**Abbreviations:** AIMS, Abnormal Involuntary Movement Scale; PR, partial responders; R, responders; F, female; M, male.
